The core idea is deceptively simple: no single AI model can capture the full complexity of human biology, so the authors propose dividing the problem among seven specialized “basic” AI agents, each dedicated to one level of biological organization. These are the Molecule, Organelle, Cell, Tissue, Organ, Organ System, and Body System AI Agents. A supervisory Full-Body AI Agent coordinates them, standardizing biomedical data, decomposing complex cross-scale questions, assigning level-specific tasks, and integrating outputs through iterative feedback loops. The framework leverages the ability of large language models to decompose high-level tasks into sub-goals, reason step by step, and plan sequential actions, while delegating quantitative and mechanistic analysis to validated domain-specific computational tools.

A central technical pillar of the proposal is the inter-level Data Commons, a shared repository designed to harmonize the fragmented landscape of biomedical data. The authors catalog an enormous ecosystem: 24 distinct omics categories, approximately 150 non-redundant biotechnologies, and 105 publicly accessible databases spanning genomics, epigenomics, transcriptomics, proteomics, radiomics, and clinical phenotypes. To make these resources interoperable, the framework specifies common data standards such as FASTA for nucleotide sequences, PDB for protein structures, DICOM for medical imaging, H5AD for single-cell data, and HL7 FHIR for electronic health records, alongside controlled vocabularies including ICD-10, SNOMED CT, and LOINC. Existing efforts such as Bioteque, which provides standardized embeddings of over 450,000 biomedical entities and 30 million relationships from more than 150 sources, illustrate what such a commons could look like in practice.

The framework also confronts a problem that is often glossed over in cross-scale modeling: data generated at different biological levels are fundamentally incompatible. Single-cell transcriptomic measurements are sparse, with zero-inflated count structures that distort downstream inference if treated naively. Spatial omics technologies operate at spot-level or probe-limited resolution, mixing multiple cell states in each measurement. Organ-level imaging captures macroscopic states shaped by modality-specific acquisition biases and reconstruction artifacts. The authors therefore propose explicit harmonization operators that translate outputs between biological levels through biologically meaningful intermediate representations. Single-cell outputs, for example, would be denoised and aggregated into mesoscale descriptors such as pathway activity or lineage composition, allowing tissue-level agents to reason without wading through high-dimensional matrices. Resolution-matching modules align sampling granularities, while uncertainty propagation ensures every output carries confidence descriptors reflecting measurement noise and sampling limitations.

Perhaps the most distinctive feature of the blueprint is its treatment of conflicting evidence. Rather than forcing consensus, the supervisory agent would maintain alternative explanations, selectively request refinement from agents with low confidence, and resolve disputes through “physiology-first” arbitration guided by uncertainty estimates and higher-level physiological constraints. Cross-scale communication is bidirectional: higher-level agents generate constraint signals that become priors guiding lower-level inference, so that organ-level claims must be supported by tissue and cellular evidence, while molecular findings must be checked against organism-level plausibility. Every interaction would be recorded in a traceable reasoning graph, storing the initiating agent, invoked tools, transformations, and uncertainty profiles, enabling complete reconstruction and auditing of multi-hop inference chains.

The authors illustrate the framework with an extended hypothetical execution trace centered on TP53, one of the most extensively studied tumor-suppressor genes. In the scenario, the Molecule AI Agent receives TP53 mutation data from resources such as TCGA, cBioPortal, ClinVar, and COSMIC, and produces a molecular dysfunction object describing the predicted functional consequence of, say, a DNA-binding-domain mutation. This object feeds the Organelle AI Agent, which integrates mitochondrial apoptosis markers, nuclear DNA-damage signals, and oxidative-stress indicators to determine whether damaged tumor cells could survive under stress. The Cell AI Agent then combines that output with single-cell transcriptomic evidence, using tools like Scanpy and Seurat to assess epithelial-to-mesenchymal transition scores, proliferation, apoptosis resistance, and immune evasion. The Tissue AI Agent evaluates spatial context through pathology and spatial transcriptomics tools such as QuPath and Squidpy, testing whether altered cells occupy invasion-supportive niches. The Organ, Organ System, and Body System agents progressively evaluate anatomical progression, dissemination through lymphatic and circulatory routes, and ultimately patient-level metastatic phenotype using clinical staging, imaging follow-up, and survival data.

Crucially, the framework does not permit the shortcut from a TP53 mutation directly to a metastasis diagnosis. If molecular, organelle, and cellular evidence support dysfunction but tissue, organ, and body-level evidence do not confirm invasion or dissemination, the system would conclude only that the tumor shows “molecular and cellular priming” without a confirmed metastatic phenotype, and would recommend additional evidence such as spatial transcriptomics of invasive margins or circulating tumor-cell assessment. This conflict-aware design is intended to prevent local signals from being overinterpreted as systemic conclusions, a common failure mode in current biomedical AI.

The second application scenario addresses drug development, where more than 90% of candidates that appear safe and effective in animal models ultimately fail in human trials. The authors describe a “Drug AI Agent” that maps the entire drug development pipeline, from target identification and compound discovery through preclinical validation, clinical trials, and post-market surveillance, onto the seven biological levels. The framework would integrate organoid and organ-on-chip models into a whole-body computational context, addressing their known limitations, including the boundedness of single-organ chips and their inability to capture chronic toxicities that emerge over weeks or months. The authors sketch an in-silico workflow involving molecular docking with tools such as AutoDock-GPU and GNINA, molecular dynamics simulations in GROMACS, generative design with DiffDock, ADMET prediction via pkCSM and Tox21 models, and retrosynthetic planning with ASKCOS. They cite real-world precedents including INS018_055, the first AI-discovered and AI-designed drug candidate for idiopathic pulmonary fibrosis to complete Phase IIa trials; the AI-discovered antibiotic halicin; and baricitinib, repurposed for COVID-19 with FDA emergency use authorization just nine months after the AI-generated hypothesis.

The Perspective is explicit about the risks of LLM-based coordination. In a benchmark study of 2,400 MIMIC patient cases, large language models performed significantly worse than physicians, with diagnostic accuracy dropping from 67.8% to 54.9% for OASST and from 65.1% to 53.9% for WizardLM when models had to gather diagnostic information autonomously; models also hallucinated nonexistent tools every two to five patients. Because a mistaken tool call or unsupported molecular interpretation could cascade into misleading tissue-, organ-, or patient-level conclusions, the framework restricts LLMs to orchestration and communication roles, requiring schema-constrained tool interfaces, ontology-consistency checks between reasoning hops, and trace-based rollback when inconsistencies emerge. MedQA-style benchmarking and interpretability methods like those demonstrated by ChatNT offer routes toward validating whether predictions rely on biologically coherent features.

The authors are candid about the substantial barriers ahead. Data fragmentation, temporal misalignment of heterogeneous datasets, the computational cost of organism-scale simulation, and the black-box nature of deep models all remain unresolved. Ethical concerns around genomic data privacy, bias in unrepresentative training data, compliance with GDPR and HIPAA, and the need for clinical validation are addressed directly, with the framework positioned as an augmentative tool whose final decisions must rest with medical professionals. A proposed modular activation strategy would keep the system scalable by engaging only the subset of biological layers relevant to a given query, escalating across scales only when uncertainty or physiological inconsistency exceeds defined thresholds, in a manner analogous to sparse activation in expert-based AI architectures.

Future work, the authors argue, must move from conceptual design to benchmarked implementation: building minimal runnable prototypes for focused biological questions, testing two- or three-level reasoning chains with real inputs, and comparing the seven-layer architecture against simpler orchestration baselines using system-level metrics such as task-decomposition fidelity, cross-scale alignment, arbitration success, convergence behavior, latency, cost, and failure rate. Whether the Full-Body AI Agent ultimately outperforms simpler alternatives remains an open empirical question. But as a coordination abstraction, it offers something biomedical AI currently lacks: a systematic way to ensure that a molecular signal suggesting pathway disruption is never mistaken for a clinical conclusion unless it remains consistent with cellular states, tissue organization, organ physiology, and the patient-level phenotype it is ultimately meant to explain.